Adenocarcinoma of the Pancreas Clinical Trials

7 recruiting

Adenocarcinoma of the Pancreas Trials at a Glance

9 actively recruiting trials for adenocarcinoma of the pancreas are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Barcelona, Castellon, and Boston. Lead sponsors running adenocarcinoma of the pancreas studies include Dana-Farber Cancer Institute, Fundación para la Investigación del Hospital Clínico de Valencia, and Boryung Pharmaceutical Co., Ltd.

Browse adenocarcinoma of the pancreas trials by phase

Treatments under study

About Adenocarcinoma of the Pancreas Clinical Trials

Looking for clinical trials for Adenocarcinoma of the Pancreas? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adenocarcinoma of the Pancreas trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adenocarcinoma of the Pancreas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas
West Virginia University40 enrolled1 locationNCT04911816
Recruiting
Phase 2

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Adenocarcinoma of the Pancreas
National Cancer Institute, Naples240 enrolled5 locationsNCT05821556
Recruiting
Not Applicable

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

Adenocarcinoma of the Pancreas
The University of Texas Health Science Center at San Antonio40 enrolled1 locationNCT07340151
Recruiting
Not Applicable

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

Pancreatic CancerPancreas CancerAdenocarcinoma of the Pancreas+1 more
HistoSonics, Inc.50 enrolled1 locationNCT06282809
Recruiting
Phase 1Phase 2

Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula

Adenocarcinoma of the PancreasAdenocarcinoma of the DuodenumAmpullary Adenocarcinoma
University Hospital, Lille36 enrolled1 locationNCT05116072
Recruiting

Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?

Adenocarcinoma of the Pancreas
Fundación para la Investigación del Hospital Clínico de Valencia70 enrolled17 locationsNCT06582342
Recruiting
Phase 2

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Pancreatic CancerAdenocarcinomaAdenocarcinoma of the Pancreas
Gulam Manji10 enrolled3 locationsNCT04543071
Recruiting
Phase 1Phase 2

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Non-small Cell Lung CancerAdvanced Pancreatic AdenocarcinomaUnresectable Pancreatic Cancer+1 more
Dana-Farber Cancer Institute100 enrolled2 locationsNCT04789486
Recruiting
Phase 1

A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

Metastatic Adenocarcinoma of the Pancreas
Boryung Pharmaceutical Co., Ltd20 enrolled2 locationsNCT06867497